Addition of @entity7652 to XXXX for Treatment of Dextran Sulfate @entity1372 -Induced @entity1960 in C57BL/6 @entity19 .

@entity16404 @entity137 @entity7652 @entity19 @entity31 @entity1372 @entity1960 @entity3504 @entity637 @entity2983 @entity1049
UNASSIGNED: @entity31 ( @entity31 ) is a common chronic remitting disease but without satisfactory treatment. Alternative medicine @entity7652 has received massive attention for its potential in @entity31 treatment. Conventional therapies with the addition of @entity7652 are becoming attractive as novel therapies in @entity31 . In the present study, we investigated the preclinical activity of a conventional oral @entity2983 ( @entity3504 ) therapy plus @entity7652 in experimental @entity1960 . A subclinical dose of @entity3504 (200 mg/kg/day) alone or @entity3504 plus @entity7652 (20 mg/kg/day) was orally administered for 30 days to C57BL/6 @entity19 with @entity1960 induced by three cycles of 2% dextran sulfate @entity1372 (DSS). The disease severity, inflammatory responses, drug accumulation and potential @entity137 of @entity1960 @entity19 were examined. The results showed that comparing to @entity3504 alone, @entity3504 plus @entity7652 more potently ameliorated DSS-induced disease severity, @entity1049 . Further, the up-regulation in mRNA level of colonic @entity637 as well as NFkB and @entity16404 phosphorylation caused by DSS were more pronouncedly reversed in animals treated with the combination therapy than those treated with @entity3504 alone. Moreover, the addition of @entity7652 to @entity3504 more significantly inhibited lymphocyte @entity637 secretion of DSS @entity19 than @entity3504 alone. In the meanwhile, no extra drug accumulation or potential @entity137 to major organs of @entity1960 @entity19 was observed with this combination treatment. In summary, our studies provide preclinical rationale for the addition of @entity7652 to @entity3504 as a promising therapeutic strategy in clinic by reducing dose of standard therapy.
